Navigating HER2-Negative Breast Cancer: Types, Treatments, and Outlook

Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026

Quick Answer: What is HER2-negative breast cancer?

HER2-negative breast cancer is a diagnosis in which breast cancer cells lack the excess HER2 protein [1] that fuels rapid growth in HER2-positive cases. These cancers are often driven by hormones like estrogen and progesterone [1] or, in triple-negative cancer, by other mechanisms. HER2 status guides whether hormone-blocking drugs, chemotherapy or newer targeted therapies will help [1].

What the research says

• HER2-low cancers can be targeted: In the phase 3 DESTINY-Breast04 trial of 557 patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan extended median progression-free survival to 9.9 versus 5.1 months and median overall survival to 23.4 versus 16.8 months compared with physician's-choice chemotherapy; drug-related interstitial lung disease or pneumonitis occurred in 12.1% of treated patients. Modi et al., N Engl J Med 2022 [2].

• Immunotherapy in triple-negative disease: In the KEYNOTE-522 trial of 1,174 patients with early triple-negative breast cancer, adding pembrolizumab to neoadjuvant chemotherapy raised the pathological complete response rate to 64.8% versus 51.2% with placebo (P<0.001) in the first interim analysis. Schmid et al., N Engl J Med 2020 [3].

Key Takeaways

What are the two main forms of HER2-negative breast cancer?

Healthcare providers classify HER2-negative cancers into two primary categories based on the presence or absence of hormone receptors [1]. This distinction is the most important factor in determining the long-term treatment strategy.

The first and most common type is HR-positive/HER2-negative (HR+/HER2-) breast cancer, which represents about 70% of all cases [1]. In these instances, the cancer cells have receptors for estrogen, progesterone, or both, meaning the body's natural hormones fuel the tumor's growth [1]. Because these cells do not have excess HER2, they are managed primarily through hormone-blocking therapies [1].

The second type is HR-negative/HER2-negative (HR-/HER2-), more commonly known as Triple-Negative Breast Cancer (TNBC) [1]. This type accounts for approximately 11% of diagnoses [1] and is defined by the absence of all three common drivers: estrogen receptors, progesterone receptors, and HER2 protein [1]. Because it lacks these targets, TNBC often requires more aggressive systemic treatments like chemotherapy and immunotherapy [1].

What are the symptoms of HER2-negative breast cancer, and when should you get screened?

The symptoms of HER2-negative breast cancer mirror those of other breast cancer types [1]. It is important to remember that early-stage cancer often presents no visible symptoms, making regular mammograms essential for early detection [1].

When symptoms do occur, they may include:

1. Physical Lumps: A new, hard lump in the breast or underarm area that does not change with the menstrual cycle [1].

2. Skin Changes: Dimpling, puckering, or redness [1] that gives the skin an "orange peel" texture.

3. Nipple Abnormalities: Sudden nipple inversion, discharge (other than breast milk), or persistent scaling and itching [1].

4. Shape Alterations: Unexplained changes in the size, shape, or symmetry of one breast [1].

How do IHC and FISH tests diagnose HER2-negative breast cancer?

To confirm a HER2-negative status, pathologists perform specialized tests on a biopsy sample. The most common is Immunohistochemistry (IHC), which uses antibodies to detect the HER2 protein on the cell surface [1]. An IHC score of 0 or 1+ is considered negative [1].

If the IHC result is ambiguous (a score of 2+), providers will order a Fluorescence in situ hybridization (FISH) test [1]. This test uses a special microscope to look directly at the HER2 gene within the cells to see if there are too many copies [1]. A normal gene count confirms the HER2-negative status [1], allowing the medical team to move forward with a targeted treatment plan.

How is HER2-negative breast cancer treated with targeted therapy?

Because HER2-negative cancers are not driven by the HER2 protein, standard HER2 drugs such as trastuzumab do not work for them, although many HER2-low cancers can be treated with the HER2-directed drug trastuzumab deruxtecan [1]. Instead, treatment is tailored to the specific subtype and stage of the cancer [1].

Management for HR+/HER2- Cancer

For the 70% of patients with hormone-sensitive cancer, Hormone Therapy is the cornerstone of treatment. Drugs like aromatase inhibitors and SERMs work by either lowering estrogen levels or blocking estrogen from reaching the cancer cells [1]. In many cases, these are paired with Targeted Therapies like CDK4/6 inhibitors, which block enzymes that help cancer cells divide [1].

Management for Triple-Negative Cancer (TNBC)

Because TNBC lacks hormone receptors, hormone therapy is ineffective [1]. Instead, Chemotherapy is the primary systemic treatment [1], often used before surgery to shrink the tumor [3]. Recent advancements have also introduced Immunotherapy (such as pembrolizumab) [1] [3], which helps the body's own immune system identify and destroy cancer cells. For patients with specific genetic mutations, PARP inhibitors may also be an option [1].

Conclusion

A diagnosis of HER2-negative breast cancer covers a wide spectrum of the disease, from the highly manageable HR+ types to the more aggressive triple-negative forms. While the terminology focuses on what the cancer lacks, the modern medical landscape is defined by what we have: a growing arsenal of targeted, hormonal, and immunological treatments. Through precise diagnostic testing and personalized care, patients today have better outcomes and more options than ever before.

Frequently Asked Questions (FAQ)

Is HER2-negative breast cancer better than HER2-positive?

It isn't necessarily "better" or "worse"; it simply requires different treatments [1]. HER2-positive cancers were once more difficult to treat, but targeted therapies have significantly improved their outlook.

What does "HR+" mean?

It stands for Hormone Receptor-positive, meaning the cancer grows in response to estrogen or progesterone [1].

Is triple-negative breast cancer always HER2-negative?

Yes, by definition, triple-negative breast cancer lacks estrogen receptors, progesterone receptors, and the HER2 protein [1].

Can HER2 status change over time?

While rare, cancer can sometimes change its biomarkers if it recurs or spreads, which is why doctors may re-test a new tumor.

Does HER2-negative cancer grow slower?

HR+/HER2- cancers often grow more slowly than HER2-positive or triple-negative types, but this varies by individual.

What is a "biomarker"?

A biological molecule (like the HER2 protein) found in blood or tissues that is a sign of a normal or abnormal process, or of a condition or disease.

Why do I need a FISH test?

A FISH test is used if the initial IHC test is unclear (a score of 2+) [1] to provide a definitive gene count.

Is chemotherapy always necessary for HER2-negative cancer?

Not always. For some early-stage HR+ cancers, hormone therapy and surgery may be sufficient.

What are BRCA1 and BRCA2?

These are inherited gene mutations that significantly increase the risk of developing breast and ovarian cancer.

Can men get HER2-negative breast cancer?

Yes, men can develop breast cancer, and the majority of male breast cancers are HR+/HER2-.

What is an aromatase inhibitor?

A type of hormone therapy that lowers estrogen levels in postmenopausal women.

What is immunotherapy?

A treatment that uses the body's immune system to fight cancer, commonly used for triple-negative breast cancer [1].

What does a "1+" IHC score mean?

It means a small amount of HER2 protein was detected, but not enough to be considered "positive".

Is HER2-negative cancer hereditary?

The HER2 status itself isn't inherited, but genetic mutations like BRCA that increase cancer risk can be [1].

What is a lumpectomy?

A surgery to remove the tumor and a small rim of healthy tissue around it, rather than the entire breast.

How often should I get a mammogram?

Recommendations vary by age and risk, but most experts suggest annual or biennial screenings starting at age 40 or 50.

What are PARP inhibitors?

Targeted drugs used for patients with BRCA mutations that prevent cancer cells from repairing their DNA.

Can diet prevent HER2-negative cancer?

While no diet can guarantee prevention, maintaining a healthy weight and limiting alcohol [1] can reduce overall risk.

What is "staging"?

A process to determine how much cancer is in the body and where it is located.

Is HR+/HER2- the most common breast cancer?

Yes, it accounts for approximately 70% of all breast cancer diagnoses [1].

What is pembrolizumab?

An immunotherapy drug (brand name Keytruda) often used to treat triple-negative breast cancer [1].

What are CDK4/6 inhibitors?

Targeted drugs that block specific proteins to stop cancer cells from dividing [1].

Does HER2-negative cancer respond to Herceptin?

No, drugs like Herceptin (trastuzumab) only work on HER2-positive cancers [1].

What is an "inverted" nipple?

A nipple that pulls inward into the breast rather than pointing out.

Can I have both HR+ and HER2+ cancer?

Yes, that is called "triple-positive" breast cancer, but it is not classified as HER2-negative.

What is a pathologist?

A doctor who studies tissues and cells to diagnose diseases like cancer.

Why is alcohol a risk factor?

Alcohol can increase estrogen levels and damage DNA, both of which contribute to breast cancer risk.

What is radiation therapy?

The use of high-energy rays to kill cancer cells, often used after surgery [1].

Is triple-negative cancer harder to treat?

It can be more challenging because it lacks the common targets for hormone and HER2 therapy [1], but new treatments are improving outcomes.

What is a biopsy?

The removal of a small piece of tissue for laboratory examination.

Can I have a baby after treatment?

Cancer treatment can affect fertility; patients should discuss fertility preservation with their doctor before starting.

What is menopause?

The time in a person's life when periods stop, affecting hormone levels and cancer risk.

What are SERMs?

Selective Estrogen Receptor Modulators, drugs that block estrogen's effects in breast tissue.

Does HER2-negative cancer cause pain?

Most breast cancers do not cause pain in the early stages, which is why screening is so important.

What is a mastectomy?

Surgery to remove the entire breast.

What is the IHC score for triple-negative cancer?

It would be 0 or 1+ (negative) for HER2, and negative for both hormone receptors [1].

Can I get a second opinion?

Yes, second opinions are common in cancer care to confirm the diagnosis and treatment plan.

How is staging determined?

Through physical exams, biopsies, and imaging tests like CT scans or MRIs.

What is "HER2-low"?

A newer category for cancers with an IHC of 1+ or 2+ (with negative FISH) that may respond to specific new targeted drugs [2].

Is there a vaccine for breast cancer?

There are no preventative vaccines, but researchers are studying therapeutic vaccines to prevent recurrence.

What is "systemic" treatment?

Treatment that travels through the entire body, like chemotherapy or hormone therapy.

Does family history always mean I'll get cancer?

No, it increases your risk, but many people with a family history never develop the disease.

What is a GnRH agonist?

A drug that suppresses the production of hormones by the ovaries.

Is HER2-negative cancer related to age?

Risk increases with age, but breast cancer can occur in younger individuals as well.

What is "ER+"?

Estrogen Receptor-positive, meaning the cancer cells have receptors for the hormone estrogen.

What is "PR+"?

Progesterone Receptor-positive, meaning the cancer cells have receptors for the hormone progesterone.

Can I use hormone replacement therapy (HRT)?

HRT for menopause symptoms can increase breast cancer risk [1] and is generally avoided after a diagnosis.

What is a "targeted" therapy?

A drug designed to attack specific molecules that help cancer cells grow and survive.

How long does hormone therapy last?

It is typically taken for 5 to 10 years to reduce the risk of the cancer returning.

What is the most important factor in my prognosis?

The stage at diagnosis and the cancer's response to initial treatment are key factors [1].

Related Reading

Antibody-Drug Conjugates (ADCs): How They Work and Side Effects explains antibody-drug conjugates for cancer.

Immunohistochemistry (IHC): What It Is, How It Works and What Results Mean explains the antibody staining test that identifies cancer type and treatment targets.

References

1. Cleveland Clinic. HER2-Negative Breast Cancer. Cleveland Clinic. Last updated February 26, 2025. https://my.clevelandclinic.org/health/diseases/her2-negative-breast-cancer

2. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20. PMID 35665782. https://doi.org/10.1056/NEJMoa2203690

3. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810-821. PMID 32101663. https://doi.org/10.1056/NEJMoa1910549

Disclaimer

The information provided in this article is for educational purposes only and should not be considered medical advice. Always consult with your healthcare team regarding any symptoms or treatment plans related to breast health.